Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to -$362123.0.

  • HCW Biologics' Change in Accured Expenses fell 17442.47% to -$362123.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year decrease of 12676.67%. This contributed to the annual value of $11.9 million for FY2024, which is 63330.14% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Change in Accured Expenses is -$362123.0, which was down 17442.47% from -$373905.0 recorded in Q2 2025.
  • HCW Biologics' 5-year Change in Accured Expenses high stood at $9.4 million for Q2 2024, and its period low was -$2.4 million during Q1 2025.
  • Its 5-year average for Change in Accured Expenses is $666614.4, with a median of $489763.0 in 2021.
  • Per our database at Business Quant, HCW Biologics' Change in Accured Expenses crashed by 25021.06% in 2022 and then skyrocketed by 180151.4% in 2024.
  • Over the past 5 years, HCW Biologics' Change in Accured Expenses (Quarter) stood at -$72913.0 in 2021, then surged by 951.96% to $621187.0 in 2022, then soared by 97.45% to $1.2 million in 2023, then plummeted by 141.45% to -$508404.0 in 2024, then grew by 28.77% to -$362123.0 in 2025.
  • Its Change in Accured Expenses was -$362123.0 in Q3 2025, compared to -$373905.0 in Q2 2025 and -$2.4 million in Q1 2025.